Serotype Distribution Among US Adults Hospitalized With Community-Acquired Pneumonia, 2019-2020.

Background: Serotype-specific urinary antigen detection (UAD) assay results can be used to estimate the serotype contribution among adults with pneumococcal community-acquired pneumonia (CAP) and to guide recommendations regarding higher-valency pneumococcal conjugate vaccines (PCVs).

Methods: Adults aged ≥18 years hospitalized with radiographic evidence of CAP were prospectively enrolled in 4 US cities from November 2019 to December 2020, overlapping the coronavirus disease 2019 (COVID-19) pandemic. Data were collected by patient interview and medical chart review. was isolated from standard-of-care respiratory samples and blood; urine collected per-protocol was tested by BinaxNOW and UAD assays. The proportions of adults with radiologically confirmed CAP (RAD CAP) testing positive for and for serotypes contained in PCV13, PCV15, and PCV20 were calculated.

Results: Among 3098 adults enrolled, 2105 (67.9%) had RAD CAP. Of these, 44.3% were ≥65 years of age, and most had a chronic medical condition (46.0%) or were immunocompromised (38.5%). was detected by any method in 214 (10.2%) RAD CAP participants, including 63 (3.0%) with serotypes covered by PCV13, 81 (3.9%) by PCV15, and 119 (5.7%) by PCV20. and PCV serotype positivity were higher before the pandemic (November 2019-April 2020) compared to during the COVID-19 pandemic (May 2020-December 2020).

Conclusions: Our study demonstrated that despite the COVID-19 pandemic, PCV serotype pneumococcus continued to cause an important proportion of adult CAP in the US. These data are useful for informing PCV recommendations and for establishing an epidemiologic baseline to assess the impact of such recommendations.